Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 4 Recurrence patterns according to different LN statuses

From: Patients with macroscopic lymph node metastasis expect poor prognosis after neoadjuvant chemotherapy in advanced ovarian cancer: a retrospective cohort study based on a single gynecological team

 

MLN group

(n = 40)

NLN group

(n = 46)a

P value

Recurrence with LNs

  

0.137

 Yes

24 (60.0%)

20 (43.5%)

 

 No

16 (40.0%)

26 (56.5%)

 

LN recurrence in the previously dissected areas

  

1.000

 Yes

1 (4.2%)

1 (5%)

 

 No

23 (95.8%)

19 (95%)

 

LN recurrence outside the abdominopelvic cavityb

  

1.000

 Yes

13 (54.2%)

10 (50%)

 

 No

11 (45.8%)

10 (50%)

 
  1. Values are expressed as the number (percentage) of patients
  2. a16 patients (34.8%) in the NLN group had received lymphadenectomy during IDS among patients experiencing recurrence
  3. bRecurrent sites included mediastinum, hilus pulmonis, axillary fossa, and neck
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us